About Apollomics Inc. - Class A Ordinary Shares (APLM)
Apollomics Inc. is a biotechnology company focused on the development of innovative cancer therapies. The company is dedicated to addressing unmet medical needs in oncology through the research and commercialization of novel drug candidates that target specific pathways associated with cancer growth and progression. By leveraging cutting-edge science and technology, Apollomics aims to create effective treatments that improve patient outcomes and quality of life for individuals battling various types of cancer. The company's strategic approach includes pursuing collaborations and partnerships to enhance its drug development pipeline. Read More
FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today announced the following update regarding changes to the Company’s board of directors (“Board”) and composition of committees.
FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced the following company operational update.
FOSTER CITY, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the fiscal year ended December 31, 2024, and highlighted clinical updates and business progress.
